Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Clinical trial NCT07220252 · RECRUITING
Trial details
- NCT number
- NCT07220252
- Sponsor
- TG Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2030-01-01
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.